Remove 2026 Remove Capital Structure Remove Equity Remove Technology
article thumbnail

Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools

Benzinga

NASDAQ: LAB ), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic (NASDAQ: SLGC ), a leader in data-driven proteomics technology, today announced that they have entered into a definitive agreement to combine in an all-stock merger. and BOULDER, Colo.,

article thumbnail

SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

Benzinga

We expect this will deliver $300 million in combined revenue by 2026. Accelerates our path to profitability through enhanced operating leverage and an anticipated $80 million in run-rate cost synergies by 2026. The capital structure of the combined company is not risky.